EQS-News

Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance

EQS-News: Medios AG / Key word(s): Quarterly / Interim Statement/Quarter Results Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance 07.05.2024 / 07:31 CET/CEST The issuer is solely responsible for the content of this announcement. Press release

 

Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance

 

• Revenue increases by 5.8% to €456.2 million in the first quarter
• Cash flow from operating activities increases to €43.4 million
• Closing of the Ceban acquisition planned for May 2024
• Guidance 2024 confirmed: Significant increase in revenue and margin expected

 

Berlin, May 7, 2024 – Medios AG ("Medios"), the leading provider of Specialty Pharma solutions in Germany, confirms its guidance for the 2024 financial year after a solid first quarter. Revenue increased by 5.8% year-on-year to €456.2 million in the period from January to March 2024 (previous year: €431.2 million). At €15.1 million (previous year: €15.0 million), EBITDA pre¹ reached the level of the same quarter of the previous year. As a result, the EBITDA pre¹ margin of 3.3% (previous year: 3.5%) was slightly lower than in the same period of the previous year. Cash flow from operating activities improved significantly in the first quarter of 2024 to €43.4 million (previous year:
€–25.3 million).

Heterogeneous sales and earnings development in the operating segments

The Pharmaceutical Supply segment achieved an increase in revenue of 8.9% to €401.0 million in the first quarter of 2024 (previous year: €368.1 million). The segment’s EBITDA pre¹ increased by 9.0% to €11.0 million (previous year: €10.1 million).

The Patient-Specific Therapies segment generated revenue of €55.1 million in the first quarter of 2024 after €62.9 million in the previous year. Around €3.5 million of this decline was attributable to the sale of Kölsche Blister GmbH in June 2023. In addition, regulatory price adjustments in some compounding areas still had a negative impact on the earnings development. As a result, the segment’s EBITDA pre¹ decreased by 9.4% to €5.9 million (previous year: €6.6 million).